معرفی
Kevin Outterson is the Austin B. Fletcher Professor of Law at Boston University School of Law and founding Executive Director and Principal Investigator of CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership funded by the U.S., U.K., and German governments, Wellcome, and the Bill & Melinda Gates Foundation. His work focuses on the legal and economic aspects of antimicrobial resistance policy, with particular emphasis on market incentives for antibiotic development.
Professor Outterson's research spans health law, intellectual property, and pharmaceutical policy, with over 90 peer-reviewed publications in leading journals including New England Journal of Medicine, Health Affairs, and The Lancet Infectious Diseases. His scholarly work examines the broken market for antibiotics and proposes innovative solutions including pull incentives, delinked funding models, and international governance frameworks. Recent publications demonstrate an increasing focus on global policy coordination, economic valuation of antibiotics, and practical implementation of incentive mechanisms across different healthcare systems.
- 2015 Leadership Award by the Alliance for the Prudent Use of Antibiotics
- Editor-in-Chief of the Journal of Law, Medicine & Ethics
- Faculty co-advisor to the American Journal of Law & Medicine
- Former chair of the Section on Law, Medicine & Health Care of the Association of American Law Schools
As Executive Director of CARB-X, Professor Outterson has secured over $800 million in grants to accelerate the development of new antibacterial products. He has testified before Congress on antimicrobial resistance and advised numerous international bodies on policy solutions. His work bridges legal scholarship, health economics, and practical policy implementation to address one of the most pressing global health security threats of our time.
